Cargando…

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis

BACKGROUND: Durvalumab is approved for the treatment of lung cancer, advanced biliary tract cancers, and is also being evaluated in many other solid organ tumors. The aim of our study is to define the incidence, etiology, and outcomes of liver injury in consecutive patients receiving durvalumab-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Swanson, Linnea A., Kassab, Ihab, Tsung, Irene, Schneider, Bryan J., Fontana, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637844/
https://www.ncbi.nlm.nih.gov/pubmed/36353563
http://dx.doi.org/10.3389/fonc.2022.984940